Target intelligence / Profile preview

UTP11 small subunit processome component (UTP11)

Target
UTP11
Molecular classification
Ribosome biogenesis factor, Small-subunit processome protein, Nucleolar protein, RNA-binding protein
01

Overview

UTP11 small subunit processome component is an RNA-binding nucleolar protein involved in the biogenesis of the 18S ribosomal RNA by binding pre-rRNA processing factor MPP10. It is a critical component of the small subunit (SSU) processome, a ribosome assembly intermediate. UTP11 is overexpressed in diverse human cancers and correlates with poor prognosis. UTP11 depletion triggers nucleolar stress, which activates p53 signaling and arrests cancer cell growth. Additionally, UTP11 regulates NRF2-dependent ferroptosis, independent of p53, contributing to its role as an oncogenic protein. Targeting UTP11 may provide an attractive strategy for cancer therapy by inducing cell death through nucleolar stress and ferroptosis

Other names
UTP11LProbable U3 small nucleolar RNA-associated protein 11UTP11 small subunit processome component2700082D03RikCGI-94LOC51118RGD1559610
02

Mechanism of action

- Induction of nucleolar stress leading to p53 activation and cancer cell growth arrest - Promotion of ferroptosis via destabilization of NRF2 mRNA and repression of SLC7A11 - Disruption of ribosome biogenesis (inhibiting 18S rRNA synthesis)

03

Biological functions

Ribosomal small subunit biogenesis (18S rRNA biosynthesis)RNA binding and processingRegulation of nucleolar stress response and p53 pathway activationRegulation of apoptosisRegulation of ferroptosis through NRF2/SLC7A11 pathwayNervous system development
04

Disease associations

Cancer (oncogenic driver, prognostic biomarker in hepatocellular carcinoma, breast cancer, colorectal cancer. Promotes survival of cancer cells and poor prognosis, targeting downstream pathways: p53, ferroptosis)
05

Safety considerations

Targeting core ribosome biogenesis factors (like UTP11) may impact normal cell growth and viability. Thus, safety must be monitored, especially in rapidly dividing tissues.Unknown off-target effects and impact on healthy tissue ribosome function.
06

Interacting drugs

No direct drugs targeting UTP11 are currently documented. However, its potential as a therapeutic target is being explored for cancer therapy through nucleolar stress and induction of ferroptosis.
07

Biomarkers

UTP11 expression level (predicts poor prognosis in cancer, especially hepatocellular carcinoma)

Beyond the preview

Go deeper on UTP11 small subunit processome component (UTP11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTP11 small subunit processome component (UTP11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call